within Pharmacolibrary.Drugs.R_RespiratorySystem.R03B_OtherDrugsForObstructiveAirwayDiseasesInhalants.R03BA02_Budesonide;

model Budesonide_1
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 3.6111111111111115e-06,
    adminDuration = 600,
    adminMass = 0.8 / 1000000,
    adminCount = 1,
    Vd = 0.0022,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.0011,
    k12 = 2.222222222222222e-06,
    k21 = 2.222222222222222e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Budesonide_1</td></tr><tr><td>ATC code:</td><td>R03BA02_1</td></tr><td>route:</td><td>inhalation</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>0.8</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>2.2</td><td>L</td></tr>
    <tr><td>clearance:</td><td>13</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Budesonide is a synthetic corticosteroid with potent glucocorticoid activity. It is commonly used for the treatment of asthma, chronic obstructive pulmonary disease (COPD), allergic rhinitis, and inflammatory bowel disease (such as Crohn's disease and ulcerative colitis). It is approved and widely used in inhaled, oral, and rectal formulations due to its high first-pass metabolism, which minimizes systemic side effects.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for healthy adults after inhaled administration (metered-dose inhaler).</p><h4>References</h4><ol><li><p>Donnelly, R, &amp; Seale, JP (2001). Clinical pharmacokinetics of inhaled budesonide. <i>Clinical pharmacokinetics</i> 40(6) 427–440. DOI:<a href=\"https://doi.org/10.2165/00003088-200140060-00004\">10.2165/00003088-200140060-00004</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11475468/\">https://pubmed.ncbi.nlm.nih.gov/11475468</a></p></li><li><p>Roberts, JK, et al., &amp; Ward, RM (2016). Pharmacokinetics of Budesonide Administered with Surfactant in Premature Lambs: Implications for Neonatal Clinical Trials. <i>Current clinical pharmacology</i> 11(1) 53–61. DOI:<a href=\"https://doi.org/10.2174/1574884710666150929100210\">10.2174/1574884710666150929100210</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26416605/\">https://pubmed.ncbi.nlm.nih.gov/26416605</a></p></li><li><p>Simeoli, R, et al., &amp; Goffredo, BM (2024). Pharmacokinetic Evaluation of Oral Viscous Budesonide in Paediatric Patients with Eosinophilic Oesophagitis in Repaired Oesophageal Atresia. <i>Pharmaceutics</i> 16(7) –. DOI:<a href=\"https://doi.org/10.3390/pharmaceutics16070872\">10.3390/pharmaceutics16070872</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39065569/\">https://pubmed.ncbi.nlm.nih.gov/39065569</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.R.R03BA02_1 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Budesonide_1;
